Table 3.

Univariate analysis of overall survival and progression-free survival

Parameter		P-value
		OS	PFS
Age	≤67 years vs. >67 years	0.69	0.21
Gender	Male vs. female	0.92	0.46
Disease stage	LD vs. ED	0.04*	<0.001*
LDH	Normal vs. Elevated	0.35	0.027*
RECIST	Responder vs. Non-responder	0.10	<0.001*
SUVmax1	≤9.5 vs. >9.5	0.63	0.21
SUVpeak1	≤7.9 vs. >7.9	0.63	0.21
MTV1	≤132 vs. >132	0.14	<0.001*
TLG1	≤592 vs. >592	0.19	<0.002*
SUVmax2	≤6 vs. >6	0.005*	<0.001*
SUVpeak2	≤4.2 vs. >4.2	0.017*	0.031*
MTV2	≤9.1 vs. >9.1	0.018*	<0.001*
TLG2	≤30 vs. >30	0.01*	0.001*
ΔSUVmax (%)	≤ −45.2 vs. > −45.2	0.004*	0.003*
ΔSUVpeak (%)	≤ −46.8 vs. > −46.8	0.001*	<0.001*
ΔMTV2.5 (%)	≤ −94.4 vs. > −94.4	0.18	0.025*
ΔTLG (%)	≤ −96.4 vs. > −96.4	0.11	0.07

OS, overall survival; PFS, progression-free survival; LDH, lactate dehydrogenase; RECIST, response evaluation criteria in solid tumor; SUVmax, maximum standardized uptake value; SUVpeak, peak standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis

*Statistically significant